Hikma Pharmaceuticals’ (HIK) Buy Rating Reaffirmed at Deutsche Bank Aktiengesellschaft

Hikma Pharmaceuticals (LON:HIK – Get Free Report)‘s stock had its “buy” rating reiterated by research analysts at Deutsche Bank Aktiengesellschaft in a research note issued on Monday,Digital Look reports. They currently have a GBX 195 target price on the stock. Deutsche Bank Aktiengesellschaft’s price objective points to a potential downside of 86.80% from the company’s current price.

Several other brokerages have also issued reports on HIK. Jefferies Financial Group boosted their price objective on shares of Hikma Pharmaceuticals from GBX 1,850 to GBX 1,870 and gave the company a “buy” rating in a report on Tuesday, May 5th. Berenberg Bank reiterated a “buy” rating and set a GBX 1,800 price target on shares of Hikma Pharmaceuticals in a research report on Tuesday, April 28th. Five equities research analysts have rated the stock with a Buy rating, Based on data from MarketBeat, the stock presently has a consensus rating of “Buy” and a consensus target price of GBX 1,687.

Get Hikma Pharmaceuticals alerts:

Get Our Latest Research Report on HIK

Hikma Pharmaceuticals Stock Performance

Shares of Hikma Pharmaceuticals stock opened at GBX 1,477 on Monday. Hikma Pharmaceuticals has a 52 week low of GBX 1,187 and a 52 week high of GBX 2,074. The business’s fifty day simple moving average is GBX 1,422.57 and its 200-day simple moving average is GBX 1,447.22. The firm has a market cap of £3.14 billion, a PE ratio of 8.16, a price-to-earnings-growth ratio of 2.38 and a beta of 0.65. The company has a quick ratio of 1.27, a current ratio of 1.82 and a debt-to-equity ratio of 61.84.

Hikma Pharmaceuticals Company Profile

(Get Free Report)

At Hikma we help put better health within reach, every day. By creating high-quality medicines and making them accessible to the people who need them, we help to shape a healthier world that enriches all our communities. We help deliver this by living our culture, delivering our strategy, and acting responsibly. We are a trusted, reliable partner and dependable source of over 820+ (as of Feb 2026) high-quality generic, specialty and branded pharmaceutical products that hospitals, physicians and pharmacists need to treat their patients across North America, MENA and Europe.

Further Reading

• Five stocks we like better than Hikma Pharmaceuticals
• SpaceX’s Historic IPO Has Already Sparked a 2X ETF Frenzy
• Cheesecake Factory Stock Is Up Over 50%—Is There Room for More CAKE?
• Royal Caribbean’s Best Quarter Ever Still Leaves a Big Question
• Lululemon’s China Backlash May Be Hiding a Bigger Valuation Story

Receive News & Ratings for Hikma Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hikma Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.